ReShape Lifesciences Inc. reported Impairment of long-lived assets for the third quarter ended September 30, 2023. For the quarter, the company reported Impairment of long-lived assets of $777,000 against $7,429,000 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.175 USD | +0.52% | +5.42% | -29.92% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 01 | Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.92% | 4.08M | |
+8.07% | 219B | |
+7.87% | 184B | |
+12.75% | 138B | |
-1.37% | 62.54B | |
+4.88% | 52.22B | |
+11.59% | 51.73B | |
+2.71% | 41.4B | |
+4.90% | 37.17B | |
+23.75% | 31.76B |
- Stock Market
- Equities
- RSLS Stock
- News ReShape Lifesciences Inc.
- ReShape Lifesciences Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2023